June 2019 - Volume 3 - S1
pp: 1075-1075

Indolent and mantle-cell non-Hodgkin lymphoma – Clinical


S101 EFFICACY AND SAFETY OF PROLONGED MAINTENANCE WITH SUBCUTANEOUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA: RESULTS OF THE PHASE III MABCUTE STUDY

Rule, S.; Gois Barreto, W.; Briones, J.; More

HemaSphere. 3(S1):1, June 2019.

S102 POLATUZUMAB VEDOTIN (POLA) + OBINUTUZUMAB (G) AND LENALIDOMIDE (LEN) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): INTERIM ANALYSIS OF A PHASE IB/II TRIAL

Abrisqueta, P.; Kahl, B.; Banerjee, L.; More

HemaSphere. 3(S1):2-3, June 2019.

S103 OBINUTUZUMAB PLUS DHAP FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION PLUS OBINUTUZUMAB MAINTENANCE PROVIDES A HIGH MRD RESPONSE RATE IN UNTREATED MCL PATIENTS, LYMA-101 TRIAL - A LYSA TRIAL

Legouill, S.; Beldi-Ferchiou, A.; Cacheux, V.; More

HemaSphere. 3(S1):3, June 2019.

S104 THE BRAF INHIBITOR VEMURAFENIB COMBINED WITH RITUXIMAB PRODUCES A HIGH RATE OF DEEP AND DURABLE REMISSIONS IN RELAPSED OR REFRACTORY HAIRY CELL LEUKEMIA: UPDATED RESULTS OF A PHASE-2 TRIAL

Tiacci, E.; De Carolis, L.; Simonetti, E.; More

HemaSphere. 3(S1):3, June 2019.

Novel agents and therapies for CLL


S105 GENETIC MARKERS AND OUTCOME IN THE CLL14 TRIAL OF THE GCLLSG COMPARING FRONT LINE OBINUTUZUMAB PLUS CHLORAMBUCIL OR VENETOCLAX IN PATIENTS WITH COMORBIDITY

Tausch, E.; Bahlo, J.; Robrecht, S.; More

HemaSphere. 3(S1):4, June 2019.

S106 HIGH EFFICACY OF VENETOCLAX PLUS OBINUTUZUMAB IN PATIENTS WITH COMPLEX KARYOTYPE (CKT) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A PROSPECTIVE ANALYSIS FROM THE CLL14 TRIAL

Al-Sawaf, O.; Lilienweiss, E.; Bahlo, J.; More

HemaSphere. 3(S1):4-5, June 2019.

S107 FIVE-YEAR FOLLOW-UP OF PATIENTS RECEIVING IBRUTINIB FOR FIRST-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA

Tedeschi, A.; Burger, J.; Barr, P.M.; More

HemaSphere. 3(S1):5-6, June 2019.

S108 SAFETY ANALYSIS OF VENETOCLAX AND IBRUTINIB FOR PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL): SECOND INTERIM ANALYSIS FROM THE PHASE II VISION HO141 TRIAL

Kater, A.P.; Dubois, J.; Kersting, S.; More

HemaSphere. 3(S1):6, June 2019.

S109 TRANSCEND CLL 004: MINIMAL RESIDUAL DISEASE NEGATIVE RESPONSES AFTER LISOCABTAGENE MARALEUCEL (LISO-CEL) IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA

Siddiqi, T.; Dorritie, K.; Soumerai, J.; More

HemaSphere. 3(S1):6-7, June 2019.

Acute myeloid leukemia - Biology & translational research - Genes and regulation


S113 GENETICS AND MODELING OF HUMAN ACUTE ERYTHROID LEUKEMIA

Fagnan, A.; Riera Piqué Borràs, M.; Ignacimouttou, C.; More

HemaSphere. 3(S1):8-9, June 2019.

Alternative donor transplantation


S114 POST-TRANSPLANT CYCLOPHOSPHAMIDE VS ATG FOR GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS IN T-REPLETE HAPLOIDENTICAL TRANSPLANTATION FOR ACUTE LYMPHOBLASTIC LEUKEMIA: A REPORT OF THE ALWP/EBMT

Nagler, A.; Labopin, M.; Ruggeri, A.; More

HemaSphere. 3(S1):9, June 2019.

S115 IMPACT OF MESURABLE RESIDUAL DISEASE POSITIVITY ON OUTCOMES FOLLOWING UNMBILICAL CORD BLOOD TRANSPLANTATION: A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT AND EUROCORD

Baron, F.; Labopin, M.; Ruggeri, A.; More

HemaSphere. 3(S1):9-10, June 2019.

S117 THE ROLE OF ANTI-THYMOCYTE GLOBULIN WITH THIOTEPA-BUSULFAN-FLUDARABINE BASED CONDITIONING IN PATIENTS UNDERGOING HAPLOIDENTICAL STEM CELL TRANSPLANT AND POST-TRANSPLANT CYCLOPHOSPHAMIDE

El-Cheikh, J.; Devillier, R.; Dulery, R.; More

HemaSphere. 3(S1):10-11, June 2019.

S118 IMPACT OF PRE-TRANSPLANT DONOR-SPECIFIC ANTI-HLA ANTIBODIES IN CORD BLOOD TRANSPLANTATION ON BEHALF OF THE TRANSPLANT COMPLICATIONS WORKING GROUP OF JSHCT

Fuji, S.; Oshima, K.; Ohashi, K.; More

HemaSphere. 3(S1):11, June 2019.

New biological and translational insights into MM


S119 THE ROLE OF RECURRENT SOMATIC ALTERATIONS IN THE NON-CODING GENOME WITH FUNCTIONAL IMPLICATIONS IN MM

Samur, M.; Szalat, R.; Aktas Samur, A.; More

HemaSphere. 3(S1):11-12, June 2019.

S121 SINGLE-CELL CHARACTERIZATION OF THE MULTIPLE MYELOMA (MM) IMMUNE MICROENVIRONMENT IDENTIFIES CD27- T CELLS AS POTENTIAL SOURCE OF TUMOR-REACTIVE LYMPHOCYTES

Botta, C.; Perez, C.; Puig, N.; More

HemaSphere. 3(S1):12-13, June 2019.

S122 THE FIRST-IN-CLASS, ORALLY AVAILABLE BMI-1 MODULATORS PTC-028 AND PTC596 DISPLAY POTENT ACTIVITY IN PRE-CLINICAL MODELS OF MULTIPLE MYELOMA

Bolomsky, A.; Muller, J.; Stangelberger, K.; More

HemaSphere. 3(S1):13, June 2019.

Mechanisms and strategies to address TKI resistance and stem cell persistence


S123 SETD2 LOSS OF FUNCTION IS A RECURRENT EVENT IN ADVANCED-PHASE CHRONIC MYELOID LEUKEMIA INDUCED BY POST-TRANSLATIONAL MECHANISMS THAT CAN BE THERAPEUTICALLY TARGETED

Mancini, M.; De Santis, S.; Monaldi, C.; More

HemaSphere. 3(S1):13-14, June 2019.

Modeling and therapeutic targeting in acute lymphoblastic leukemia I


S129 TP53 SOMATIC MUTATIONS AS PRE-LEUKEMIC EVENTS IN ACUTE LYMPHOBLASTIC LEUKEMIA

Chitadze, G.; Stengel, A.; John-Klaua, C.; More

HemaSphere. 3(S1):16-17, June 2019.

Molecular Implications in MDS


S135 NGS-BASED COPY-NUMBER ANALYSIS IN MORE THAN 2,000 PATIENTS WITH MYELOID NEOPLASMS

Saiki, R.; Shiozawa, Y.; Yoshizato, T.; More

HemaSphere. 3(S1):19-20, June 2019.

Hematopoiesis, stem cells and microenvironment


S137 DNA METHYLATION DYNAMICS IDENTIFY LINEAGE-SPECIFIC REGULATION PATTERNS OF HEMATOPOIETIC DIFFERENTIATION

Stäble, S.; Krämer, S.; Langstein, J.; More

HemaSphere. 3(S1):20, June 2019.

S139 JUNCTIONAL ADHESION MOLECULE A (JAM-A) IS A CRITICAL REGULATOR OF HSC HOMING AND MAINTENANCE OF STEM CELL QUIESCENCE

Cao, B.; Hart, C.; Iberl, S.; More

HemaSphere. 3(S1):21, June 2019.

Advances in the management of thalassemia


S140 RESULTS FROM THE PHASE 3 NORTHSTAR-3 STUDY EVALUATING LENTIGLOBIN GENE THERAPY IN PATIENTS WITH TRANSFUSION-DEPENDENT β-THALASSAEMIA AND A β0 OR IVS-I-110 MUTATION AT BOTH ALLELES OF THE HBB GENE

Kulozik, A.E.; Locatelli, F.; Yannaki, E.; More

HemaSphere. 3(S1):21-22, June 2019.

S141 CLINICAL OUTCOMES OF LENTIGLOBIN GENE THERAPY FOR TRANSFUSION-DEPENDENT β-THALASSAEMIA (TDT) FOLLOWING COMPLETION OF THE NORTHSTAR (HGB-204) STUDY

Walters, M.C.; Kwiatkowski, J.L.; Rasko, J.E.J.; More

HemaSphere. 3(S1):22, June 2019.

S144 A MULTICENTRE, RANDOMIZED, NON-INFERIORITY TRIAL COMPARING THE EFFICACY OF DEFERIPRONE VERSUS DEFERASIROX IN PEDIATRIC PATIENTS AFFECTED BY TRANSFUSION-DEPENDENT HEMOGLOBINOPATHIES (DEEP-2 TRIAL)

Kattamis, A.; Felisi, M.; Reggiardo, G.; More

HemaSphere. 3(S1):23-24, June 2019.


Best abstracts


S145 PHASE 3 RANDOMIZED STUDY OF DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD) VERSUS VTD IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: PART 1 CASSIOPEIA RESULTS

Moreau, P.; Attal, M.; Hulin, C.; More

HemaSphere. 3(S1):24-25, June 2019.

S147 RESULTS FROM THE RANDOMIZED PLACEBO-CONTROLLED PHASE 3 HOPE TRIAL OF VOXELOTOR IN ADULTS AND ADOLESCENTS WITH SICKLE CELL DISEASE

Vichinsky, E.; Hoppe, C.C.; Ataga, K.I.; More

HemaSphere. 3(S1):25-26, June 2019.

S149 FIXED-DURATION VENETOCLAX PLUS OBINUTUZUMAB IMPROVES PROGRESSION-FREE SURVIVAL AND MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL AND COMORBIDITIES

Fischer, K.; Al-Sawaf, O.; Bahlo, J.; More

HemaSphere. 3(S1):26-27, June 2019.


Acute lymphoblastic leukemia – Biology & translational research


PF151 RAS/MAPK ACTIVATION COOPERATES WITH GAIN OF CHROMOSOME 21 IN B CELL LEUKEMIA AND IS AN ATTRACTIVE TARGET TO IMPROVE THE OUTCOME OF DS CHILDREN WITH B-ALL

Laurent, A.P.; Siret, A.; Ignacimouttou, C.; More

HemaSphere. 3(S1):28, June 2019.

PF153 MLL-AF4 CAUSES ABERRANT UPREGULATION OF PROM1 (CD133) IN ACUTE LYMPHOBLASTIC LEUKEMIA BY CONTROLLING ENHANCER-PROMOTER INTERACTIONS

Godfrey, L.; O’Byrne, S.; Crump, N.T.; More

HemaSphere. 3(S1):29, June 2019.

PF155 COMBINATION OF FLOTETUZUMAB, A CD123 X CD3 BISPECIFIC DART® MOLECULE, AND BLINATUMOMAB, A CD19 X CD3 BITE MOLECULE, TO PREVENT ANTIGEN ESCAPE IN B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA

Lukic, D. Slavkovic; Duell, J.; Davidson-Moncada, J.; More

HemaSphere. 3(S1):29-30, June 2019.

PF158 TARGETING ONCOGENIC NOTCH1 IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WITH A NEW SELECTIVE SERCA INHIBITOR CAD204520

Marchesini, M.; Gherli, A.; Winter, A.-M. Lund; More

HemaSphere. 3(S1):31, June 2019.

PF160 IKZF1 DELETIONS DO NOT HAVE A STRONG IMPACT ON EVENT FREE SURVIVAL IN PATIENTS WITH B-PRECURSOR ALL TREATED ON THE UKALL14 TRIAL (ISRCTN 66541317)

Mitchell, R.J.; Kirkwood, A.A.; Barretta, E.; More

HemaSphere. 3(S1):31-32, June 2019.

PF162 FREQUENCY AND PROGNOSTIC IMPACT OF ZEB2 H1038/Q1072 MUTATIONS IN CHILDHOOD B-OTHER ACUTE LYMPHOBLASTIC LEUKEMIA

Zaliova, M.; Potuckova, E.; Lukes, J. Jr.; More

HemaSphere. 3(S1):33, June 2019.

Acute lymphoblastic leukemia – Clinical


PF172 PROSPECTIVE COMPARISON OF SANGER SEQUENCING VS NEXT GENERATION SEQUENCING FOR ROUTINE BCR-ABL1 KINASE DOMAIN MUTATION SCREENING IN PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS

Soverini, S.; Martelli, M.; Bavaro, L.; More

HemaSphere. 3(S1):37-38, June 2019.

PF174 GERIATRIC ASSESSMENT-BASED TREATMENT OF ELDERLY PHILADELPHIA-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS. RESULTS OF THE GIMEMA LAL1104 PROTOCOL

Chiaretti, S.; Cesini, L.; Di Raimondo, F.; More

HemaSphere. 3(S1):39, June 2019.

PF175 MULTICENTRE STANDARDIZATION OF MINIMAL RESIDUAL DISEASE DETECTION AND QUANTITATION USING THE EUROCLONALITY-NGS ASSAY

Svaton, M.; Fronkova, E.; Kotrova, M.; More

HemaSphere. 3(S1):39-40, June 2019.

PF176 MONOCYTIC SWITCH AND DISCREPANCY BETWEEN FLOW CYTOMETRIC AND MOLECULAR MINIMAL RESIDUAL DISEASE ARE FREQUENT IN DUX4 REARRANGED AND PAX5-P80R MUTATED B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA

Novakova, M.; Vakrmanova, B.; Slamova, L.; More

HemaSphere. 3(S1):40-41, June 2019.

PF177 NATION-WIDE PROSPECTIVE, REAL-TIME MONITORING OF PEGYLATED E.COLI AND ERWINIA ASPARAGINASE THERAPY IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA AND NON-HODGKIN LYMPHOMA IN BELGIUM

Mondelaers, V.; Lammens, T.; Dedeken, L.; More

HemaSphere. 3(S1):41, June 2019.

PF182 CLINICOBIOLOGIC CHARACTERISTICS AND OUTCOME OF ELDERLY FRAIL PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA INCLUDED IN A SPECIFIC PROTOCOL (ALL-07FRAIL)

Ribera, J.M.; García-Calduch, O.; Gil, C.; More

HemaSphere. 3(S1):43, June 2019.

PF184 EFFICACY OF CONSOLIDATION CHEMOTHERAPY FOR PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA WHO ACHIEVED COMPLETE REMISSION BY FIRST COURSE OF REMISSION INDUCTION THERAPY

Shigematsu, A.; Ota, S.; Kobayashi, R.; More

HemaSphere. 3(S1):44, June 2019.